 Dr. Ways Expertise in Late-Stage Clinical Development in Therapeutics Areas of High Unmet Medical Meet Supports Spruces Goal to Expand Portfolio of Indications for Tildacerfont San Francisco, Calif. June 24, 2021 Spruce Biosciences, Inc. Nasdaq: SPRB, a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced the appointment of Kirk Ways, M.D. 